AU
Aura Biosciences, Inc.
AURA · NASDAQ
$6.99 -2.10% (-$0.15)
1M -9.81%
Market Cap $723.0M
P/E Ratio -
Div. Yield -
ROE 73.18%
Bulios Fair Price
$6.42
8.2% downside
Current Price
$6.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AURA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
80 /100
Cheap P/B 2.29x
EV/EBITDA N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 11.21%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 73.18%
ROA 37.63%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 16.82x
Debt/Equity 0.05x
Net debt/EBITDA N/A
Stability
61 /100
Moderate EPS volatility 5.21%
Profitable years 0
Beta 0.40x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AURA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Natalie C. Holles
Employees
113
Headquarters
Boston
Upcoming events
12 NOV
Earnings
Upcoming earnings report